Body and Mind (Body and Mind) Debt-to-EBITDA : -5.58 (As of Jan. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Body and Mind Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Body and Mind's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $1.37 Mil. Body and Mind's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was $11.06 Mil. Body and Mind's annualized EBITDA for the quarter that ended in Jan. 2024 was $-2.23 Mil. Body and Mind's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was -5.58.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Body and Mind's Debt-to-EBITDA or its related term are showing as below:

BMMJ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.36 Med: -0.58 Max: 3.08
Current: -1.06

During the past 13 years, the highest Debt-to-EBITDA Ratio of Body and Mind was 3.08. The lowest was -1.36. And the median was -0.58.

BMMJ's Debt-to-EBITDA is ranked worse than
100% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.665 vs BMMJ: -1.06

Body and Mind Debt-to-EBITDA Historical Data

The historical data trend for Body and Mind's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Body and Mind Debt-to-EBITDA Chart

Body and Mind Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.70

3.08

-0.54

-1.36

Body and Mind Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-EBITDA	Get a 7-Day Free Trial															-4.29	27.82	-0.47	-3.72	-5.58

Competitive Comparison of Body and Mind's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Body and Mind's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Body and Mind's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Body and Mind's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Body and Mind's Debt-to-EBITDA falls into.

Body and Mind Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Body and Mind's Debt-to-EBITDA for the fiscal year that ended in Jul. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.776	+	18.119)	/	-14.633
	=	-1.36

Body and Mind's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(1.368	+	11.055)	/	-2.228
	=	-5.58

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.

Body and Mind (OTCPK:BMMJ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Body and Mind Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Body and Mind's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Body and Mind (Body and Mind) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Body and Mind Inc (OTCPK:BMMJ) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

BAMM:Canada

Address

750-1095 West Pender Street, Vancouver, BC, CAN, V6E 2M6

Website

https://www.bodyandmind.com

Body and Mind Inc is a multi-state cannabis operator, which has retail, distribution, cultivation, and/or processing operations in Nevada, California, Arkansas, Ohio and Illinois. It has developed the marquis lifestyle Body and Mind brand in Nevada with penetration into dispensaries and has expanded its brand and products to dispensaries in California. The Body and Mind brand appeals to a wide range of cannabis consumers with products including flowers, oils, extracts (wax, live resin, ambrosia), and edibles. The Company Operates in Three segments; Wholesale, Retail, and All others. The Majority of revenue is derived from the Retail segment.